ReviewEpilepsia2013
Issues related to development of new antiseizure treatments.
Review in Epilepsia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Vagus Nerve Stimulation differentially modulates P3b in responders and non-responders: toward a biomarker of therapeutic efficacy.Frontiers in neuroscience · 2026Article
- Development of Novel Alaninamide Derivatives with Anticonvulsant Activity and Favorable Safety Profiles in Animal Models.International journal of molecular sciences · 2024Article
- Review
- Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation.The Journal of pharmacology and experimental therapeutics · 2023Article
- Translational Considerations in the Development of Intranasal Treatments for Epilepsy.Pharmaceutics · 2023Review
- GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAPharmacology & therapeutics · 2022Review
- From the North Sea to Drug Repurposing, the Antiseizure Activity of Halimide and Plinabulin.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel.Patient related outcome measures · 2022Article
- Identification of New Compounds with Anticonvulsant and Antinociceptive Properties in a Group of 3-substituted (2,5-dioxo-pyrrolidin-1-yl)(phenyl)-Acetamides.International journal of molecular sciences · 2021Article
- Neuropharmacology of Antiseizure Drugs.Neuropsychopharmacology reports · 2021Review
- Efficacy and tolerability of antiseizure drugs.Therapeutic advances in neurological disorders · 2021Review
- The unmet need for rapid epileptic seizure termination (REST).Epilepsy & behavior reports · 2021Review
- Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats.Epilepsia · 2020Article
- The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy.Neuropharmacology · 2020Review
- Molecular Mechanisms and Structural Basis of Retigabine Analogues in Regulating KCNQ2 Channel.The Journal of membrane biology · 2020Article
- N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a Broad-Spectrum Antiepileptic Drug.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- The Positive Allosteric Modulator ofThe Journal of pharmacology and experimental therapeutics · 2020Article
- Anticonvulsant Essential Oils and Their Relationship with Oxidative Stress in Epilepsy.Biomolecules · 2019Review
- Zebrafish-Based Discovery of Antiseizure Compounds from the North Sea: Isoquinoline Alkaloids TMC-120A and TMC-120B.Marine drugs · 2019Article
- Embelin Prevents Seizure and Associated Cognitive Impairments in a Pentylenetetrazole-Induced Kindling Zebrafish Model.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.